CMPS250117P5000
- 0.98
- 0.000.00%
COMPASS Pathways Newsroom
Compass Pathways Common Stock To Be Added To The Nasdaq Biotechnology Index
Earnings Week Ahead: FDX, NKE, CCL, BB, ACN, MU, and More
Compass Pathways to Participate in December Investor Conferences
COMPASS Pathways: Institutional Pressure Amid $43M Market Cap Decline, What's Next For This Psychedelics Co?
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday
Express News | U.S.-Listed Shares of ATAI Life Sciences up 9.1%
Express News | GH Research Shares up 4.1%
Express News | Compass Pathways Shares up 11.9%
Express News | Shares of Psychedelic Drug Developers Rise After Rfk Jr Picked for Top US Health Agency Role
RFK and the 'MAHA Trade': Vaccine Makers Down, Psychedelic Shares up
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
Strategic Opportunity in COMPASS Pathways Amid Extended Phase 3 Trials and Conservative Price Target
Massachusetts Psychedelics Legalization Initiative Poised to Fail
Top 3 Health Care Stocks You'll Regret Missing In November
BTIG Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $12
Morgan Stanley Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $17
Massachusetts may be the next stop for legalization, is it a good investment opportunity for psychedelic drug concept stocks?
On Tuesday, Massachusetts voters will decide whether the state will legalize psilocybin, a psychedelic compound found in "magic mushrooms", worth paying attention to related concept stocks.
Legalizing Psychedelics: Is Massachusetts Next?
Compass Pathways Cuts 30% of Workforce on Phase 3 Trial Delays